SBI Securities’s Travere Therapeutics TVTX Stock Holding History

SBI Securities’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.95K	Buy	140 +59	+73%	+$2.62K	﹤0.01%	1952
2026 Q1	$2.41K	Sell	81 -286	-78%	-$8.55K	﹤0.01%	2359
2025 Q4	$14K	Buy	367 +273	+290%	+$8.88K	﹤0.01%	1581
2025 Q3	$2.25K	Sell	94 -17	-15%	-$320	﹤0.01%	2380
2025 Q2	$1.64K	Buy	111 +28	+34%	+$464	﹤0.01%	2471
2025 Q1	$1.49K	Sell	83 -1	-1%	-$20	﹤0.01%	2421
2024 Q4	$1.46K	Buy	+84	New	+$1.49K	﹤0.01%	2435

Other funds holding TVTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

HCMT

Highland Capital Management (Tennessee) Memphis, Tennessee $2.17B AUM 54.74% 1-Year Est. Return

SBI Securities's TVTX Position: Q2 2026 in Review

SBI Securities increased its Travere Therapeutics (TVTX) stake by 73% in Q2 2026, buying an estimated $2.62K and bringing the position to 140 shares worth $7.95K. The position accounts for ﹤0.01% of the portfolio, ranked #1952.

SBI Securities first reported a position in TVTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $14K in Q4 2025. 35 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

SBI Securities held 140 shares of Travere Therapeutics worth $7.95K as of Q2 2026.
SBI Securities bought 59 Travere Therapeutics shares in Q2 2026, an estimated $2.62K.
Travere Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #1952 holding.
SBI Securities first reported a position in Travere Therapeutics in Q4 2024 and has held it in 7 quarters since.
SBI Securities's Travere Therapeutics position peaked at $14K in Q4 2025.
35 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.